Cabral-Miranda, G;
Heath, MD;
Gomes, AC;
Mohsen, MO;
Montoya-Diaz, E;
Salman, AM;
Atcheson, E;
... Bachmann, MF; + view all
(2017)
Microcrystalline Tyrosine (MCT®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria.
Vaccines
, 5
(4)
, Article 32. 10.3390/vaccines5040032.
Preview |
Text
Cruz Gomes_Microcrystalline Tyrosine (MCT®). A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malari_VoR.pdf - Published Version Download (3MB) | Preview |
Abstract
Microcrystalline Tyrosine (MCT®) is a widely used proprietary depot excipient in specific immunotherapy for allergy. In the current study we assessed the potential of MCT to serve as an adjuvant in the development of a vaccine against malaria. To this end, we formulated the circumsporozoite protein (CSP) of P. vivax in MCT and compared the induced immune responses to CSP formulated in PBS or Alum. Both MCT and Alum strongly increased immunogenicity of CSP compared to PBS in both C57BL/6 and BALB/c mice. Challenge studies in mice using a chimeric P. bergei expressing CSP of P. vivax demonstrated clinically improved symptoms of malaria with CSP formulated in both MCT and Alum; protection was, however, more pronounced if CSP was formulated in MCT. Hence, MCT may be an attractive biodegradable adjuvant useful for the development of novel prophylactic vaccines.
| Type: | Article |
|---|---|
| Title: | Microcrystalline Tyrosine (MCT®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria |
| Location: | Switzerland |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.3390/vaccines5040032 |
| Publisher version: | https://doi.org/10.3390/vaccines5040032 |
| Language: | English |
| Additional information: | © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
| Keywords: | vaccine, malaria, adjuvant, MCT |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10070061 |
Archive Staff Only
 |
View Item |
